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The combination of 5-ﬂuorouracil-folinic acid and oxaliplatin has led to a signiﬁcant improvement of chemotherapy efﬁcacy in
advanced pretreated colorectal cancer. The objective of the present study was, considering the oxaplatin-5-ﬂuorouracil-folinic
acid combination, to examine the impact of one given drug on the cellular determinants of cytotoxic activity of the other drug.
These cellular factors were analysed on the human colon cancer cell line WiDr in clinically relevant conditions of drug
exposure (‘De Gramont’ schedule) with oxaliplatin-folinic acid during 2 h followed by 5-ﬂuorouracil 48 h. The DNA binding of
oxaliplatin was signiﬁcantly reduced by the presence of 5-ﬂuorouracil but this effect was time-dependent and after 50 h the
platinum incorporated into DNA was identical in controls and in the drug combination. In the presence of oxaliplatin, there
was less formation of FUH2 which is the ﬁrst catabolite produced in the cascade of 5-ﬂuorouracil metabolic degradation. The
effects of drugs on cell cycle were quite different from one drug to the other with oxaliplatin inducing a shift towards G2
accumulation and 5-ﬂuorouracil-folinic acid to a greater proportion of cells in G1–S. When oxaliplatin and 5-ﬂuorouracil-folinic
acid were combined the cell cycle effects were very similar to that of the 5-ﬂuorouracil-folinic acid sequence alone. Oxaliplatin
was able to reduce thymidylate synthase activity with a marked impact 28 h after the beginning of cell exposure to the drug.
The 5-ﬂuorouracil-folinic acid drug sequence led to a profound reduction in thymidylate synthase activity and this decrease
was not markedly enhanced by the presence of oxaliplatin. Regarding apoptosis, changes in mitochondrial membrane
permeability were observed in the presence of the tested drugs and the impact of 5-ﬂuorouracil-folinic acid was greater than
that of oxaliplatin. The addition of oxaliplatin did not amplify the action of 5-ﬂuorouracil-folinic acid upon mitochondrial
membrane permeability change. The presence of oxaliplatin itself did not modify the intracellular concentration of total
reduced folates. The fact that oxaliplatin may reduce 5-ﬂuorouracil catabolism could be central in explaining the supra-additive
interaction between these drugs.
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Colorectal cancer remains a leading cause of cancer deaths in
western countries and approximately half of all patients develop
metastatic disease carrying a poor prognosis. Chemotherapy still
represents the treatment of choice for palliative purposes. The efﬁ-
cacy of chemotherapy in advanced colorectal cancer has
signiﬁcantly progressed during the last two decades. Folinic acid
(FA) modulation of 5-ﬂuorouracil (FU) has markedly increased
the tumour response rate and, more recently, new drugs have
emerged in the arena of colorectal cancer treatment. Irinotecan
and oxaliplatin (Oxa) are representative of these new active drugs.
Irinotecan (CPT 11) is a topoisomerase I inhibitor which prolongs
patient survival as a second-line treatment in advanced colorectal
cancer resistant to FU (Van Cutsem et al, 1999). Oxa displays
activity not only in patients with platinum-sensitive malignancies
such as ovarian tumours but also in those with colorectal cancer,
a disease known for its resistance to both cisplatin and carboplatin
(Judson and Kelland, 2000). Recently, combinations of FUFA and
irinotecan or of FUFA and Oxa have led to a further improvement
of chemotherapy efﬁcacy in advance pretreated colorectal cancer
(Andre ￿ et al, 1998; Ducreux et al, 1999). Importantly, a recent
controled trial has established the superiority of Oxa-FUFA over
FU FA in terms of response rate and progression-free survival
(De Gramont et al, 2000). The high antitumour efﬁcacy of this
combination protocol is in agreement with preclinical data
(Raymond et al, 1997) showing the synergistic cytotoxic activity
of the Oxa-FUFA association.
The objective of the present study was, when considering the
Oxa-FUFA combination, to examine the impact of one given drug
on the cellular determinants of cytotoxic activity of the other drug.
Different potentially relevant cellular parameters for the activity of
combined drugs were analysed on the human colon cancer cell line
WiDr in clinically relevant conditions of drug exposure. The tested
drug sequence was Oxa-FA during 2 h followed by FU during 48 h.
This sequence faithfully matches the currently applied clinical
protocol derived from the ‘De Gramont’ schedule (De Gramont
et al, 2000). The choice of cellular parameters was dictated by
the respective mechanisms of action of FU and Oxa. These para-
meters were: the incorporation of platinum (Pt) in nucleic acids,
the levels of thymidylate synthase (TS) activity and TS protein,
the intracellular proﬁle of FU metabolism, the incorporation of
FU metabolites in nucleic acids, the intracellular levels of reduced
folates and cell cycle analysis. In addition, the impact on apoptosis
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For this latter purpose, change in mitochondrial membrane perme-
ability was examined as it is one of the key events initiating the
apoptotic process.
METHODS
Chemicals
All the chemicals were obtained from Sigma Chemical Co (St
Quentin Fallavier, France) and were of the highest purity available.
Regular DMEM and glutamine were obtained from Whittaker
(Verviers, Belgium) and foetal bovine serum from Dutscher
(Brumath, France). Penicillin and streptomycin were obtained from
Merieux (Lyon, France). FU and Oxa were the pharmaceutical
forms obtained from Roche (Neuilly/Seine, France) and Sanoﬁ
Synthelabo (Gentilly, France), respectively. FA (racemic mixture)
was from Sigma Chemical Co.
Drug administration schedule
The human colorectal cancer cell line, WiDr, was used in the
present study. Cells were routinely cultured in DMEM supplemen-
ted with 10% foetal bovine serum, 2 mM glutamine, 50000 units
71
penicillin and 80 mM streptomycin in a humidiﬁed incubator
(Sanyo, Japan) at 378C with an atmosphere containing 8% CO2.
One week before commencement of the experiments, the cells were
grown in a folate-controlled medium (folic acid-free DMEM
supplemented with 40 nM of DL-5 methyltetrahydrofolate and
0.1 mM of L-ascorbate) to simulate as closely as possible the
physiological conditions encountered in humans (Kones, 1990).
The above folate-controlled medium was used throughout the
experiments.
Cells were plated in 96-well microtitration plates (100 ml
well
71) to obtain exponential growth for the whole duration of
the experiment (initial cell density was 2500 cells per well).
Twenty-four hours later, cells were exposed to the drugs. Cyto-
toxic efﬁcacy of drugs taken alone was ﬁrst considered. This
permitted the determination of individual IC50 values (MTT test,
Carmichael et al, 1987). Oxa (at IC50=19.5 mM) and d, l FA
(10 mM) were applied for 2 h followed by FU during 48 h (at
IC50=13.5 mM).
The cytotoxic effects resulting from this drug combination were
checked in previously described experimental conditions (Fischel et
al, 1998 unshown experiments). For a drug combination, the calcu-
lation of the Chou and Talalay (1984) combination index indicates
the resulting effect of the drug association. A combination index at
1.00 means simple additivity, below 1 means synergy and higher
than 1 means antagonism. A mean combination index of 0.8 was
found in our experiment conﬁrming the existence of slight syner-
gistic (supra-additive) cytotoxic activity (Fischel et al, 1998).
Cellular parameters were analysed between 2 and 98 h after the
onset of different drug applications. Treated and control cells were
collected at different sampling times (2, 8, 28, 50, 74, 98 h after the
onset of Oxa applications). All investigations were duplicated at a
distance.
Cell cycle analysis
The cell cycle was analysed by FACS according to the Vindelov and
Christensen (1990) method. The percentage of cells in different cell
cycle phases was determined by Modﬁt software.
Evaluation of mitochondrial membrane permeability
Cells were treated with or without various concentrations of drugs
as described above. At various intervals, cells were washed with
PBS, trypsinised and then placed in DMEM medium.
The measuring of DCm was performed with a cationic lipophi-
lic ﬂuorochrome: 3,3' dihexyloxacarbocyanine iodide (DiOC6(3))
purchased from Sigma. Cells were incubated at 378C for 15 min
in the presence of DiCO6(3) 40 nM, then placed on ice followed
by addition of propidium iodide 10 mgm l
71. The ﬂuorochrome
incorporations were immediately analysed using a Becton Dickin-
son FACScan ﬂow cytometer at an excitation wavelength of
488 nm. PI was used in all samples to exclude dead cells from
the analysis. DiOC6(3) ﬂuorescence was recorded in FL1 and PI
was recorded in FL3. The percentage of apoptosis cells was calcu-
lated from an FL1/FL3 scattergram. All experiments were repeated
three times.
TS measurements and reduced folate determination
. TS activity was measured according to the tritium-release assay
described by Spears and Gustavsson (1988). The assay consisted
in incubating 25 mL of cytosol with
3H-dUMP (1 mM ﬁnal con-
centration) and 5,10-methylenetetrahydrofolate CH2FH4,
(0.62 mM ﬁnal concentration) in a total volume of 55 mL. After
0 (for blank substraction), 10, 20, and 30 min of incubation at
378C, the reaction was stopped in ice. The excess of
3H-dUMP
was removed by adding 300 mL of activated charcoal (15%) con-
taining 4% trichloroacetic acid (5-min centrifugation at
14000 g, room temperature). The
3H2O formed during the in-
cubation was then counted in an aliquot of the above superna-
tant. Results were expressed as fmoles of
3H2O formed per min
per mg of protein, based on the linear regression obtained from
the incubation times. The sensitivity limit was 10 fmol
min
71 mg
71 prot. Inter-assay reproducibility was evaluated
through repeated analysis of single-use aliquots of a pooled cy-
tosol: n=5, mean=1110 fmol min
71 mg
71 prot, s.d.=78.59 fmol
min
71 mg
71 prot, CV=7.08%.
. Concentration of total reduced folates (CH2FH4+FH4) and total
TS protein were measured with the radioenzymatic method pre-
viously described by Bunni et al (1988). The ternary stable com-
plex
3HFdUMP-TS-CH2FH4 was used as a trap for the
measurement of either TS or total reduced folates:
. Measurement of TS protein with excess of
3HFdUMP and
CH2FH4.
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Figure 1 Time course of Pt concentration in DNA for the WiDr cell line
(as % of maximum incorporation: 2 h exposure Oxa alone (two indepen-
dent experiments). Solid and open squares and dashed line: Oxa alone.
Solid and open triangles and solid line: Oxa+FUFA. The Pt incorporations
are statistically different between the two conditions Oxa vs Oxa+FUFA.
P=0.0055 (paired t-test on all shown data).
Molecular impacts of oxaliplatin-5FU
JL Fischel et al
1163
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1162–1168. Measurement of total reduced folates with excess of
3HFdUMP
and TS (presence of formaldehyde allowing the conversion of
FH4 into CH2FH4).
. The excess of radioactivity was retained on Sephadex columns
and the eluted fraction was counted by liquid scintillation.
The sensitivity limit for TS was 0.010 pmol mg
71 prot with a
CV=15%. The sensitivity limit for total reduced folates was
0.3 pmoles mg
71 prot with a CV=10%.
Drug incorporations in nucleic acids
Platinum incorporation into DNA was measured as follows: after
isolation of DNA on Qiagen1 columns by ionic strength elution,
DNA platinum incorporation was measured using Atomic Absorp-
tion Spectrophotometry.
14C FU incorporation into RNA and DNA was determined as
follows: WiDr cells growing exponentially in 25 cm
2 ﬂasks were
put in contact at different exposure times –8, 28, 50, 74, 96 h with
3H FU (13.5 mM, speciﬁc activity 56 mCi mMole
71) with or with-
out FA (10 mM) and Oxa (19.6 mM) DNA and RNA were isolated
on Qiagen1 columns. Radioactivity incorporation was evaluated
on a liquid scintillation counter.
Analysis of intracellular metabolism of 5-FU
3H FU metabolites were separated by HPLC and counted on line
by radioactivity monitoring as described previously (Ciccolini et
al, 2000). Exponentially growing cells were exposed to various
combination of 100 mCi of tritiated FU (ﬁnal concentration
2 mM). Cells were harvested and cytosols were isolated for HPLC
analysis. The HPLC consisted of an HP 1090 (Hewlett Packard)
system coupled with an A 200 radioactive ﬂow detector (Packard).
Separation of tritiated metabolites was achieved using a Lichro-
spher 100 RP 18 5 mM column (Hewlett Packard) eluted by
50 mM K2HPO4 (pH 6.8) containing 1 mM tetrabutyl ammonium
nitrate and 12% (0–9 min) to 16% (9–60 min) methanol.
Statistical analysis
Comparisons between different tested conditions were done with
Wilcoxon non parametric paired tests for experiments described
in Figures 1, 2A,B and 3. Comparisons between different tested
conditions were done with Mann-Whitney unpaired non para-
metric test for experiments described in Figures 5A,B and 6.
RESULTS
Figure 1 depicts the impact of the presence of FU on the incor-
poration of Pt into DNA. Although not superimposable due to
experiments performed at distance, the results shown in Figure 1
point out that DNA binding of Oxa was signiﬁcantly reduced by
the presence of FU but this effect was time-dependent and after
50 h the Pt incorporated into DNA was identical in controls
(Oxa alone) and in the drug combination (Oxa FUFA sequence).
The presence of Oxa was found to modify the intracellular
metabolic proﬁle of FU. Under Oxa, there was less formation of
FUH2 (Figure 2A), which is the ﬁrst catabolite produced in the
cascade of FU metabolic degradation. Conversely, more FU anabo-
lites were formed in the presence of Oxa (Figure 2B). When
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Figure 2 (A) Time course of FUH2 concentration (as % of total FU de-
rived chemical species). Solid square and solid line: FUFA alone. Open
square and dashed line: FUFA+Oxa. Bars represent Standard Deviations
(two independent experiments). The two curves are statistically different
P=0.0042 (paired t-test). (B) Time course of anabolites concentration
(sum of FUrd, FUMP, FUDP, FUTP, FdUrd, FdUMP, FdUDP, FdUTP). Solid
square and solid line: FUFA alone. Open square and dashed line: FU-
FA+Oxa. Bars represent Standard Deviations (two independent experi-
ments). The two curves are statistically different P=0.0096 (paired t-test).
10
8
6
4
2
0
5
F
U
 
i
n
c
o
r
p
o
r
a
t
e
d
 
(
p
m
o
l
e
s
 
µ
g
–
1
 
n
u
c
l
e
i
c
 
a
c
i
d
)
0        10       20       30       40       50       60       70       80       90     100
Time (h)
Figure 3 Time course incorporation of
14CFU in nucleic acids. Solid
square and solid line: DNA, FUFA alone. Open square and dashed line:
DNA, FUFA+Oxa. Solid triangle and solid line: RNA, FUFA alone. Open
triangle and dashed line: RNA, FUFA+Oxa. Bars represent Standard Devia-
tions (two independent experiments). The two curves of RNA incorpora-
tion are statistically different P=0.0066. The two curves of DNA
incorporation are statistically different P=0.0.156 (paired t-test).
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14CFU into nucleic acids,
and contrary to expectations, there were fewer FU-related
compounds present in nucleic acids following the Oxa FUFA
sequence as compared to FUFA alone (Figure 3).
The respective impacts of Oxa and Oxa_FUFA on cell cycle
organisation are detailed in Table 1. These effects on cell cycle
are quite different from one drug to the other with Oxa inducing
a shift towards G2 accumulation and FUFA leading to a greater
proportion of cell in G1–S and a lower proportion in G2 phase.
It is interesting to note that when Oxa and FUFA were combined
the cell cycle effects were very similar to that of the FUFA sequence
alone (Table 1).
The modiﬁcations in TS activity and TS protein levels under
drug applications are shown in Figure 4A and B respectively. This
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Table 1 Time course of the impact of drugs on cell cycle
Cell cycle (% cells)
Apoptosis (mitochondrial
Experimental conditions Time (h) G1 S G2 permeability)
2
Control mean 56.54 33.60 9.86 ND
s.d. 6.13 4.99 1.22 ND
OXA mean 52.55 36.76 10.68 ND
s.d. 5.17 2.59 2.99 ND
FUFA mean 53.61 36.03 10.35 ND
s.d. 3.76 1.33 2.74 ND
OXA FUFA mean 53.92 37.22 8.86 ND
s.d. 3.08 1.65 2.12 ND
8
Control mean 52.87 35.67 11.46 3.85
s.d. 0.16 0.29 0.19 0.79
OXA mean 51.50 41.63 6.87 3.70
s.d. 2.71 3.52 1.54 0.78
FUFA mean 52.89 42.25 4.86 3.75
s.d. 1.83 1.48 0.52 1.03
OXA FUFA mean 52.29 42.00 5.71 3.18
s.d. 0.49 0.60 0.15 0.95
28
Control mean 55.67 34.68 9.65 4.03
s.d. 4.35 5.61 1.30 0.55
OXA mean 40.22 23.27 36.51 5.80
s.d. 1.35 4.04 2.69 1.07
FUFA mean 51.65 47.79 0.59 5.28
s.d. 7.78 7.18 0.65 0.71
OXA FUFA mean 55.27 42.79 1.94 6.04
s.d. 2.73 4.14 1.48 1.34
50
Control mean 60.88 27.04 12.08 4.11
s.d. 3.77 4.32 0.68 0.88
OXA mean 35.42 20.11 44.47 8.19
s.d. 7.84 7.82 0.93 3.26
FUFA mean 61.86 38.08 0.07 11.26
s.d. 2.30 2.24 0.05 2.71
OXA FUFA mean 59.55 40.32 0.12 10.86
s.d. 5.57 5.65 0.13 5.71
74
Control mean 66.29 22.76 10.82 4.82
s.d. 6.23 3.16 3.71 1.36
OXA mean 23.44 48.29 28.28 10.00
s.d 3.14 14.75 11.87 2.75
FUFA mean 4.87 87.46 7.67 31.06
s.d. 1.06 6.10 5.54 12.09
OXA FUFA mean 3.34 91.75 4.91 30.33
s.d. 0.86 5.00 4.70 10.83
98
Control mean 56.73 30.36 12.91 6.05
s.d. 15.50 9.98 5.52 0.61
OXA mean 38.16 32.19 29.65 9.81
s.d. 8.36 14.02 5.93 1.60
FUFA mean 5.81 86.49 7.70 34.26
s.d. 4.86 7.63 4.88 11.20
OXA FUFA mean 4.98 87.81 7.21 30.54
s.d. 4.65 8.96 4.45 8.46
For cell cycle analysis and evaluation of mitochondrial membrane permeability, refer to Materials and Methods. Unit for the quantiﬁcation of mitochon-
drial membrane permeability is the percentage of stained cells. Experiments were repeated three times at distance.
Molecular impacts of oxaliplatin-5FU
JL Fischel et al
1165
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1162–1168reduction in TS activity of the control cells may be attributable to
progressive cellular conﬂuence in the small well plates. It appears
that Oxa alone is able to reduce TS activity with a marked impact
28 h after the beginning of cell exposure to the drug. The FUFA
drug sequence leads to a profound reduction in TS activity.
Although this decrease is enhanced in its early phase (8 h) by
the presence of Oxa (Figure 4A) the ‘FUFA alone’ curve and the
‘FUFA+OXA’ curve are almost identical. An early, marked and
sustained rebound in TS protein is observed after cell exposure
to FUFA. This rebound was found to be maintained in the
presence of Oxa (Figure 4B).
Changes in mitochondrial membrane permeability were
observed in the presence of the tested drugs. These effects are
detailed in Table 1. The impact of FUFA is greater than that of
Oxa. The maximal effect of Oxa is observed at 74 h whereas FUFA
has maximal impact at 98 h. Globally, the addition of Oxa does
not amplify the action of FUFA upon mitochondrial membrane
permeability change.
The intracellular evolution of total reduced folates is shown in
Figure 5. The initial decrease in total reduced folates is due to
the changing of the medium from 10 mM FA during the ﬁrst 2 h
of drug exposure to normal medium conditions. The presence of
Oxa itself does not modify the intracellular concentration of
reduced folates. Noteworthy, it was found that a marked decrease
in reduced folate levels occurred in the presence of FUFA. This
time proﬁle of intracellular reduced folates was very similar to that
observed when adding Oxa to FUFA (Figure 5).
DISCUSSION
The objective of the present study was, when considering the Oxa-
FUFA combination, to examine the impact of one given drug on
the cellular determinants of cytotoxic activity of the other drug.
To that end, the individual cellular targets of the considered drugs
were examined. The clinically relevant drug sequence consisting in
Oxa-FA, 2 h followed by FU, 48 h (De Gramont et al, 2000), was
adopted in the present study. The supra-additive interaction which
had previously been shown (Fischel et al, 1998) was conﬁrmed in
the present study on the WiDr human colon cancer cell line using
the same conditions (drugs, concentration, time of exposure) used
for the previously published results. The presence of cytotoxic
synergy between Oxa and FU had been previously reported by
Raymond et al (1997) with both in vitro and in vivo data on
human HT 29 colon cancer xenografts. In this latter study, exam-
ining possible explanatory factors, the authors failed to show that
FU could signiﬁcantly modify the tumoural total Pt DNA binding
of Oxa during Oxa-FUFA combination treatment. In the present
study, it was shown that the addition of FU to OXA resulted in
a decrease of Pt binding to DNA (Figure 1). However, this reduc-
tion of Pt binding is moderate and one of the possible reasons for
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Figure 4 (A) Time course of TS activity. Solid square and solid line: Con-
trol without drugs. Open square and dashed line: Oxa alone. Solid diamond
and solid line: FUFA alone. Open diamond and dashed line: FUFA+Oxa.
Bars represent Standard Deviations (two independent experiments). The
curves Control and Oxa alone do not differ signiﬁcantly. FUFA alone and
FUFA+Oxa do not differ signiﬁcantly. Control and FUFA alone differ signif-
icantly P=0.0163. Oxa alone and FUFA+Oxa differ signiﬁcantly P=0.0034.
Non parametric unpaired test. (B) Time course of TS protein. Solid square
and solid line: Control without drugs. Open square and dashed line: Oxa
alone. Solid diamond and solid line: FUFA alone. Open diamond and
dashed line: FUFA+Oxa. Bars represent Standard Deviations (two inde-
pendent experiments). The two curves control and Oxa alone do not differ
signiﬁcantly. FUFA alone and FUFA+Oxa do not differ signiﬁcantly. Control
and FUFA alone differ signiﬁcantly P50.01. Oxa alone and FUFA+Oxa dif-
fer signiﬁcantly P50.001.
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Figure 5 Time course of total reduced folates concentration (logarith-
mic scale, s.d. varied between 0.009 and 1.94). Solid square and solid line:
control without drugs. Open square and dashed line: Oxa alone. Solid dia-
mond and solid line: FUFA alone. Open diamond and dashed line: FU-
FA+Oxa. The two curves: control and Oxa alone are not statistically
different. FUFA alone and FUFA+Oxa are not statistically different. Control
and FUFA alone are statistically different P=0.0469. Oxa alone and FU-
FA+Oxa are statistically different P=0.039.
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lie in the fact that FU anabolites can be fraudulously incorporated
into RNA and DNA (Grem, 2000) and this incorporation may
compromise the binding of Pt to nucleic acids. Conversely, and
probably for the same reasons of reciprocal impairment of nucleic
acid drug binding, it was found that, during cell exposure to Oxa-
FUFA, there were fewer FU anabolites incorporated into nucleic
acids as compared to what is observed with the FUFA sequence
alone (Figure 3).
In the present study, using ﬂow cytometry analysis, it was shown
that the FUFA sequence induces an accumulation of cells in the G1
early S phase. This observation is in agreement with known
comparable data (Pizzorno et al, 1995) recently conﬁrmed by
Backus et al (2001). The impact of Oxa on cell cycle with an
increased proportion of cells in the G2 phase also concurs with
the cell cycle effects of platinum derivatives (Mastbergen et al,
2000). Interestingly, after Oxa and FUFA combination, the organi-
sation of cells within the cellular cycle (G1–S shift) was
superimposable to that observed following FUFA alone (Table 1).
This accumulation of cells in S phase is compatible with a slow-
down of cell proliferation in agreement with the decrease in TS
activity which was observed in the present study. Indeed, cell
proliferation and TS activity are closely related as recently under-
lined by the data of Grem et al (2001).
The enzyme dihydropyrimidine dehydrogenase (DPD) regulates
the FU catabolic route in liver and, importantly, at the tumoural
cell level (Beck et al, 1994). The impact of the variability in
tumoural DPD activity on FU cytotoxic activity has been
previously demonstrated with both in vitro (Fischel et al, 1995)
and in vivo data (Etienne et al, 1995). This resulted in the recent
development of DPD inhibitors aimed at optimising FU-based
chemotherapy (Hoff and Pazdur, 1999; Diasio, 2000). DPD activity
was previously thought to be inhibited by cisplatin, a clinically-
proven FU modulator (Leteurtre et al, 1990; Nishiyama et al,
1999). Recent pharmacokinetic studies have suggested that Oxa
may inhibit FU catabolism (Papamichael et al, 1998), although this
ﬁnding was not conﬁrmed by other investigators (Graham et al,
2000). The present investigation included a close examination of
the main FU metabolic routes. At this level, it appears that in
the presence of Oxa there was a signiﬁcant decrease in the intracel-
lular levels of FUH2. This points to the possibility that Oxa may
inhibit DPD activity. Although a direct impact on DPD activity
by Oxa was not tested in the present study, this potential DPD
inhibition may be of prime importance for tumours which overex-
press DPD since it has been shown that DPD-related resistance
may be circumvented by the use of DPD inhibitors (Fischel et al,
1995). In this view, it is interesting to emphasise that new clinical
responses have been observed when adding Oxa to FUFA in colo-
rectal cancer patients resistant to FUFA (Andre ￿ et al, 1998; Garuﬁ
et al, 2000). The shift towards fewer catabolites and more anabo-
lites of FU in the presence of Oxa was not however translated in
the present study by an increase in FU anabolite incorporation into
nucleic acids (Figure 3). The relative excess of the FU anabolite
pool in the presence of Oxa may be at the origin of the more
pronounced TS inhibition in the presence of Oxa FUFA (Figure
5A) but globally the impact of FUFA or OxaFUFA on TS activity
was superimposable. Interestingly, it was also demonstrated that
Oxa itself is able to inhibit TS activity (Figure 5A) but this effect
occurs later than the initial marked depletion in TS activity already
induced by FUFA. This direct impact of Oxa on TS activity should
be kept in mind and further explored in preclinical investigations
or clinical studies with different Oxa-FUFA schedules. Other
authors have pointed out an effect of Oxa on TS with a smaller
FU-induced TSmRNA increase when Oxa is added to Fu (Plasencia
et al, 2001). In contrast, the present data did not show that the
presence of Oxa modiﬁed the FU-induced TS protein increase
which had been previously described by Chu et al (1993).
Optimal inhibition of TS by FU required the formation of a
ternary complex between TS, ﬂuorodeoxyuridine monophosphate
(a key anabolite of FU) and a reduced folate, CH2HF4 (Keyo-
marsi and Moran, 1988). Experimental studies have established
that the stabilisation of the ternary complex is enhanced by
the presence of high levels of CH2FH4 (Moran and Scanlon,
1991). On this basis, clinical data have been provided that show
better antitumour efﬁcacy when FU is combined with leucovorin
(folinic acid), a precursor of CH2FH4 (Etienne et al, 1996). We
reported, in cancer patients treated by FU-based chemotherapy,
that, at pretreatment stage, the tumoural concentration of
reduced folates was a predictor of an objective response to treat-
ment (Etienne et al, 1995). Cisplatin has been previously shown
to upregulate the intracellular concentration of reduced folates
(Vitols et al, 1987). We thus examined the possible impact of
Oxa on the intracellular levels of total reduced folates. It was
found that, in comparison to FUFA, the Oxa-FUFA sequence
did not signiﬁcantly modify the fate of the intracellular proﬁle
of reduced folates. The present study included an examination
of drug-induced apoptotic events by considering the key step
of apoptosis at the mitochondrial level. Both Oxa and FUFA
were able to alter mitochondrial permeability with time-modu-
lated effects (Table 1). It must be underlined that FUFA was
more active than Oxa and that the addition of Oxa to FUFA
did not change the impact on mitochondrial permeability already
generated by FUFA. Other apoptotic pathways, like FAS-induced
apoptosis, should be studied more closely as this pathway has
been recently shown to play a major role in FU-mediated toxi-
city (Petak et al, 2000).
The present study examined the effects on respective cellular
determinants of drug activity when combining Oxa and FUFA.
The investigations covered the impact on drug targets, drug meta-
bolism, cell cycle effect and apoptosis. Among the various factors
explored, many failed to provide objective mechanistic explanations
for the synergistic interaction between Oxa and FUFA in particular
nucleic acid binding of respective drugs and intracellular concen-
tration in reduced folates. In our opinion, the fact that Oxa may
reduce FU catabolism at the DPD level could be central in explain-
ing the supra-additive interaction between Oxa and FUFA.
According to this hypothesis a DPD inhibitor could reduce the
synergy of the Oxa FUFA combination. This must be kept in mind
for further combinations between Oxa and recently-developed FU
oral prodrugs containing a DPD inhibitor. It is possible that other
molecular mechanisms may contribute to the supra-additive cyto-
toxic effects of the Oxa-FUFA combination. The present data may
provide useful rational grounds for discussion when testing clinical
conﬁrmation of the impact of Oxa on FU catabolism. In this
framework, exploring lymphocytic and tumoural DPD activity
under Oxa treatment seems relevant.
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